U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07449364) titled 'Allogeneic Human Mesenchymal Stem Cell Infusion for Frailty Patient' on Feb. 25.
Brief Summary: Subjects will be provided a written informed consent to participate in the study and then undergo any screening. Subjects who meet all the inclusion criteria and none of the exclusion criteria based on the screening test results will be included into the study. At treatment day, the subjects will be administered 100 million cells of investigational product for 30 minutes for each package using a syringe pump. After 4 weeks (1 month) of Investigational product administration, the subjects will visit the study site to evaluate the safety an...